ArticleAnimals : an open access journal from MDPI2026
Evaluation of the Serological Baseline Values of Broiler Chickens Jointly Vaccinated with Infectious Bronchitis H + 120 and GI-13 Preparations Under Field Conditions.
Article in Animals : an open access journal from MDPI, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Infectious bronchitis virus (IBV) is a highly infectious disease of chickens posing a major threat to poultry production worldwide. Due to genetic and antigenic variability, it is difficult to establish one universal protocol for vaccination against IB. The protectotype vaccination strategy, combining antigenically distinct vaccine strains, offers broader cross-protection than homologous IBV vaccination approaches. This field study aimed to establish serological baseline values in broiler chickens in a protectotype vaccination program using Avishield IB H-120 and Avishield IB GI-13, and to evaluate the program's efficacy under field conditions on commercial farms where heterologous IBV genotypes were detected. The study was conducted on 25 broiler farms in 2023-2024. Day-old chicks were vaccinated via coarse spray. Blood samples were taken from them at six weeks of age and analyzed using IDEXX and BioChek ELISAs, and cecal tonsils were tested by real-time RT-PCR. Production performance was assessed using the European production efficiency factor (EPEF), with a cut-off value of 360. No IB-related clinical signs were reported, and the mean EPEF of the included farms was 408.7. The detected IBV genotypes were Mass + 793B, 793B, and 793B + VAR2. The presence of heterologous VAR2 did not negatively impact flock health or performance. Preliminary serological baseline values for vaccinated, non-VAR2 farms were established at 891-1332 (in chicks tested with the IDEXX ELISA) and 4193-5204 (in those tested with the BioChek assay). The H-120 + GI-13 program demonstrated high field efficacy, reliable serological profiles, and cross-protection in the presence of heterologous IBV. Continuous monitoring of IBV genotypes remains essential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.